Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA22029PK" target="_blank" >RIV/61988987:17110/21:A22029PK - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/21:73609588 RIV/00843989:_____/21:E0108820 RIV/00098892:_____/21:N0000083
Result on the web
<a href="https://www.mdpi.com/2076-3425/11/2/141" target="_blank" >https://www.mdpi.com/2076-3425/11/2/141</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/brainsci11020141" target="_blank" >10.3390/brainsci11020141</a>
Alternative languages
Result language
angličtina
Original language name
Cerebrospinal Fluid Levels of Chromogranin A in Parkinson's Disease and Multiple System Atrophy
Original language description
Background: Chromogranin A (CgA) and other peptides from the chromogranin- secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD). Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 mu g/L; p = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; p = 0.014). There was no significant difference in CSF CgA between PD and MSA patients (p = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA. Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
<a href="/en/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molecular, cellular and clinical approach to healthy ageing</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Brain Sciences
ISSN
2076-3425
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
2
Country of publishing house
CH - SWITZERLAND
Number of pages
6
Pages from-to
—
UT code for WoS article
000622243200001
EID of the result in the Scopus database
—